Financials in USD. Standardized financial statements.
A compact view of how Intra-Cellular Therapies, Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $680.85M | $464.37M | $249.13M | $81.71M | $22.53M | $60,613 | $0 | $245,837 | $330,702 | $91,364 |
| Revenue Growth? | +46.6% | +86.4% | +204.9% | +262.7% | +37071.5% | 0.0% | -100.0% | -25.7% | +262.0% | 0.0% |
| Cost of Revenue? | $56.96M | $33.74M | $20.44M | $8.03M | $1.90M | $477,121 | $368,673 | $79.42M | $93.83M | $139,626 |
| Gross Profit? | $623.89M | $430.63M | $228.69M | $73.67M | $20.64M | -$416,508 | -$368,673 | -$79.17M | -$93.50M | -$48,262 |
| Gross Margin? | +91.6% | +92.7% | +91.8% | +90.2% | +91.6% | -687.2% | 0.0% | -32205.6% | -28273.4% | -52.8% |
| Operating Expenses? | $740.61M | $590.01M | $492.31M | $359.36M | $251.86M | $154.07M | $162.27M | $103.09M | $118.59M | $105.91M |
| Operating Income? | -$116.72M | -$159.38M | -$263.63M | -$285.69M | -$231.23M | -$154.01M | -$162.27M | -$102.84M | -$118.26M | -$105.81M |
| EBITDA? | -$116.72M | -$158.85M | -$262.97M | -$285.15M | -$230.70M | -$153.53M | -$161.90M | -$102.63M | -$115.13M | -$104.65M |
| Income Before Tax | -$74.20M | -$139.04M | -$256.25M | -$284.12M | -$226.99M | -$147.72M | -$155.13M | -$98.83M | -$115.36M | -$104.79M |
| Income Tax Expense | $473,000 | $636,000 | $6,000 | $5,631 | $13,513 | $1,600 | $1,600 | -$1.06M | $1.07M | $1,600 |
| Net Income? | -$74.68M | -$139.67M | -$256.26M | -$284.13M | -$227.01M | -$147.72M | -$155.13M | -$97.77M | -$116.43M | -$104.79M |
| EPS? | $-0.72 | $-1.46 | $-2.72 | $-3.50 | $-3.23 | $-2.68 | $-2.84 | $-2.12 | $-2.69 | $-2.91 |
| Diluted EPS? | $-0.72 | $-1.46 | $-2.72 | $-3.50 | $-3.23 | $-2.68 | $-2.84 | $-2.12 | $-2.69 | $-2.91 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality